DK3902803T3 - Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft - Google Patents
Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft Download PDFInfo
- Publication number
- DK3902803T3 DK3902803T3 DK19845796.2T DK19845796T DK3902803T3 DK 3902803 T3 DK3902803 T3 DK 3902803T3 DK 19845796 T DK19845796 T DK 19845796T DK 3902803 T3 DK3902803 T3 DK 3902803T3
- Authority
- DK
- Denmark
- Prior art keywords
- mat2a
- aza
- cancer
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785519P | 2018-12-27 | 2018-12-27 | |
| PCT/US2019/068652 WO2020139991A1 (en) | 2018-12-27 | 2019-12-27 | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3902803T3 true DK3902803T3 (da) | 2023-02-13 |
Family
ID=69400625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19845796.2T DK3902803T3 (da) | 2018-12-27 | 2019-12-27 | Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US12077534B2 (da) |
| EP (1) | EP3902803B1 (da) |
| JP (3) | JP7418441B2 (da) |
| KR (2) | KR20250093588A (da) |
| CN (1) | CN113454085B (da) |
| AR (1) | AR117544A1 (da) |
| AU (1) | AU2019416349B2 (da) |
| CA (1) | CA3124952C (da) |
| CL (1) | CL2021001721A1 (da) |
| CO (1) | CO2021009879A2 (da) |
| CR (1) | CR20210410A (da) |
| DK (1) | DK3902803T3 (da) |
| EA (1) | EA202191801A1 (da) |
| ES (1) | ES2942310T3 (da) |
| FI (1) | FI3902803T3 (da) |
| GE (1) | GEP20237519B (da) |
| HR (1) | HRP20230161T1 (da) |
| HU (1) | HUE061834T2 (da) |
| IL (1) | IL284326B2 (da) |
| JO (1) | JOP20210172A1 (da) |
| LT (1) | LT3902803T (da) |
| MA (1) | MA54608B1 (da) |
| MD (1) | MD3902803T2 (da) |
| MX (1) | MX2021007829A (da) |
| MY (1) | MY206578A (da) |
| NZ (1) | NZ777391A (da) |
| PE (1) | PE20212090A1 (da) |
| PH (1) | PH12021551490A1 (da) |
| PL (1) | PL3902803T3 (da) |
| PT (1) | PT3902803T (da) |
| RS (1) | RS64135B1 (da) |
| SA (1) | SA521422405B1 (da) |
| SG (1) | SG11202106637SA (da) |
| SI (1) | SI3902803T1 (da) |
| SM (1) | SMT202300109T1 (da) |
| TW (1) | TWI816962B (da) |
| UA (1) | UA127525C2 (da) |
| WO (1) | WO2020139991A1 (da) |
| ZA (1) | ZA202104423B (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| EP3894396A1 (en) | 2018-12-10 | 2021-10-20 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| IL300147A (en) | 2020-07-31 | 2023-03-01 | Tango Therapeutics Inc | History Piperidin-1-yl-N-pyridin-3-yl-2-oxaacetamide is useful for the treatment of MTAP-deficient and/or MTA-accumulating cancer |
| WO2022052924A1 (zh) * | 2020-09-11 | 2022-03-17 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
| CN115141202A (zh) * | 2021-03-29 | 2022-10-04 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| WO2022253242A1 (zh) * | 2021-06-02 | 2022-12-08 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a抑制剂 |
| TW202327600A (zh) | 2021-10-20 | 2023-07-16 | 香港商英科智能有限公司 | 甲硫胺酸腺苷轉移酶２ａ（ｍａｔ２ａ）抑制劑及其用途 |
| EP4448517A1 (en) * | 2021-12-17 | 2024-10-23 | Tango Therapeutics, Inc. | Crystalline form of n-(6-amino-5-methylpyridin-3-yl)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide, pharmaceutical compositions and methods of use thereof |
| JP7741987B2 (ja) * | 2021-12-21 | 2025-09-18 | 南京正大天晴制薬有限公司 | メチオニンアデノシルトランスフェラーゼ２ａの複素環阻害剤 |
| WO2023169554A1 (zh) * | 2022-03-11 | 2023-09-14 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| AU2023299635A1 (en) | 2022-06-27 | 2025-01-02 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Tricyclic compounds and uses thereof |
| KR20240051860A (ko) | 2022-10-13 | 2024-04-22 | 한미약품 주식회사 | 신규한 트리사이클 유도체 화합물 및 이의 용도 |
| WO2024183778A1 (zh) * | 2023-03-06 | 2024-09-12 | 甘李药业股份有限公司 | 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途 |
| WO2024255802A1 (zh) * | 2023-06-14 | 2024-12-19 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a杂环抑制剂的盐、晶型及其制备方法 |
| WO2025166260A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025166215A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166274A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025166257A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166229A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic amidino compounds as prmt5 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| EP1315726A1 (en) | 2000-08-31 | 2003-06-04 | F. Hoffmann-La Roche Ag | 7- oxo pyridopyrimidines as inhibitors of cellular proliferation |
| ATE346064T1 (de) | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| JP2014512337A (ja) | 2011-01-28 | 2014-05-22 | ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | スチルベン類似体およびがんを処置する方法 |
| US20160115164A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA46092A (fr) | 2016-08-31 | 2021-04-21 | Agios Pharmaceuticals Inc | Inhibiteurs de processus métaboliques cellulaires |
| UA125970C2 (uk) | 2017-05-22 | 2022-07-20 | Янссен Фармасьютікалз, Інк. | Заміщені похідні індоліну як інгібітори реплікації вірусів денге |
| US11524960B2 (en) * | 2018-03-30 | 2022-12-13 | Servier Pharmaceuticals Llc | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer |
| MA54609A (fr) * | 2018-12-27 | 2022-04-06 | Les Laboratoires Servier Sas | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer |
| US20220251081A1 (en) * | 2019-05-31 | 2022-08-11 | Les Laboratoires Servier | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
-
2019
- 2019-12-27 US US17/418,442 patent/US12077534B2/en active Active
- 2019-12-27 EP EP19845796.2A patent/EP3902803B1/en active Active
- 2019-12-27 MA MA54608A patent/MA54608B1/fr unknown
- 2019-12-27 SI SI201930515T patent/SI3902803T1/sl unknown
- 2019-12-27 MY MYPI2021003553A patent/MY206578A/en unknown
- 2019-12-27 LT LTEPPCT/US2019/068652T patent/LT3902803T/lt unknown
- 2019-12-27 TW TW108148216A patent/TWI816962B/zh active
- 2019-12-27 ES ES19845796T patent/ES2942310T3/es active Active
- 2019-12-27 PH PH1/2021/551490A patent/PH12021551490A1/en unknown
- 2019-12-27 AR ARP190103903A patent/AR117544A1/es unknown
- 2019-12-27 PE PE2021001086A patent/PE20212090A1/es unknown
- 2019-12-27 MD MDE20211082T patent/MD3902803T2/ro unknown
- 2019-12-27 DK DK19845796.2T patent/DK3902803T3/da active
- 2019-12-27 GE GEAP201915703A patent/GEP20237519B/en unknown
- 2019-12-27 UA UAA202104321A patent/UA127525C2/uk unknown
- 2019-12-27 SG SG11202106637SA patent/SG11202106637SA/en unknown
- 2019-12-27 HR HRP20230161TT patent/HRP20230161T1/hr unknown
- 2019-12-27 JP JP2021538127A patent/JP7418441B2/ja active Active
- 2019-12-27 KR KR1020257020196A patent/KR20250093588A/ko active Pending
- 2019-12-27 FI FIEP19845796.2T patent/FI3902803T3/fi active
- 2019-12-27 CA CA3124952A patent/CA3124952C/en active Active
- 2019-12-27 HU HUE19845796A patent/HUE061834T2/hu unknown
- 2019-12-27 KR KR1020217023828A patent/KR102823567B1/ko active Active
- 2019-12-27 JO JOP/2021/0172A patent/JOP20210172A1/ar unknown
- 2019-12-27 CR CR20210410A patent/CR20210410A/es unknown
- 2019-12-27 WO PCT/US2019/068652 patent/WO2020139991A1/en not_active Ceased
- 2019-12-27 IL IL284326A patent/IL284326B2/en unknown
- 2019-12-27 PL PL19845796.2T patent/PL3902803T3/pl unknown
- 2019-12-27 SM SM20230109T patent/SMT202300109T1/it unknown
- 2019-12-27 EA EA202191801A patent/EA202191801A1/ru unknown
- 2019-12-27 MX MX2021007829A patent/MX2021007829A/es unknown
- 2019-12-27 AU AU2019416349A patent/AU2019416349B2/en active Active
- 2019-12-27 CN CN201980092742.2A patent/CN113454085B/zh active Active
- 2019-12-27 PT PT198457962T patent/PT3902803T/pt unknown
- 2019-12-27 RS RS20230240A patent/RS64135B1/sr unknown
- 2019-12-27 NZ NZ777391A patent/NZ777391A/en unknown
-
2021
- 2021-06-25 ZA ZA2021/04423A patent/ZA202104423B/en unknown
- 2021-06-25 CL CL2021001721A patent/CL2021001721A1/es unknown
- 2021-06-27 SA SA521422405A patent/SA521422405B1/ar unknown
- 2021-07-27 CO CONC2021/0009879A patent/CO2021009879A2/es unknown
-
2023
- 2023-12-11 JP JP2023208546A patent/JP2024015340A/ja active Pending
-
2024
- 2024-08-05 US US18/794,610 patent/US20250214988A1/en active Pending
-
2025
- 2025-07-04 JP JP2025113748A patent/JP2025133887A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3902803T3 (da) | Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft | |
| IL277665A (en) | Heterocyclic inhibitors of MAT2A and methods of use for cancer therapy | |
| IL288395A (en) | Mat2a tricyclic inhibitors and methods for use in cancer therapy | |
| IL284324A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| DK3678668T3 (da) | ENPP1-inhibitorer og deres anvendelse til behandling af kræft | |
| DK3826667T3 (da) | Claudin6-antistoffer og fremgangsmåder til behandling af kræft | |
| DK3455259T5 (da) | Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling | |
| DK3285809T3 (da) | Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3842429T3 (da) | Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer | |
| DK3727248T3 (da) | Indretninger og fremgangsmåde til behandling af bruxisme | |
| DK3807316T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer | |
| DK3988541T3 (da) | Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse | |
| DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3328864T3 (da) | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser | |
| DK3325623T3 (da) | Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft | |
| DK3755816T3 (da) | Fremgangsmåder til påvisning og behandling af prostatacancer | |
| DK3601296T3 (da) | 2-oxo-thiazolderivater som a2a-inhibitorer og forbindelser til anvendelse ved behandling af cancere | |
| DK3293201T3 (da) | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer | |
| DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi | |
| DK3630772T3 (da) | Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere | |
| DK3468923T3 (da) | Fluorescerende vandbehandlingsforbindelser og fremgangsmåde til anvendelse | |
| DK3543405T3 (da) | Fremgangsmåde og indretning til behandling af jord | |
| DK3790879T3 (da) | Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft |